Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients
NCT02057289Phase 1Terminated
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of micafungin in fungal infection, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Pharmacokinetics of Micafungin at 96 hours. Started Jan 2014; status: terminated.
02
Drugs
micafungin
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT02057289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057289.